These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16432140)

  • 1. Pilot trial of etanercept in the treatment of inclusion-body myositis.
    Barohn RJ; Herbelin L; Kissel JT; King W; McVey AL; Saperstein DS; Mendell JR
    Neurology; 2006 Jan; 66(2 Suppl 1):S123-4. PubMed ID: 16432140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
    Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
    Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.
    Martínez-Taboada VM; Rodríguez-Valverde V; Carreño L; López-Longo J; Figueroa M; Belzunegui J; Mola EM; Bonilla G
    Ann Rheum Dis; 2008 May; 67(5):625-30. PubMed ID: 18086726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inclusion body myositis: diagnosis, pathogenesis, and treatment options.
    Solorzano GE; Phillips LH
    Rheum Dis Clin North Am; 2011 May; 37(2):173-83, v. PubMed ID: 21444018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity.
    Jackson CE; Barohn RJ; Gronseth G; Pandya S; Herbelin L;
    Muscle Nerve; 2008 Apr; 37(4):473-6. PubMed ID: 18236463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
    Guis S; Balandraud N; Bouvenot J; Auger I; Toussirot E; Wendling D; Mattei JP; Nogueira L; Mugnier B; Legeron P; Landt O; Serre G; Roudier J; Roudier C
    Arthritis Rheum; 2007 Dec; 57(8):1426-30. PubMed ID: 18050183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-based evaluation of etanercept in patients with rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Wang EC; Khalidi N
    J Rheumatol; 2006 Apr; 33(4):665-70. PubMed ID: 16568506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials.
    Dalakas MC
    Neurol Sci; 2003 Oct; 24 Suppl 4():S256-9. PubMed ID: 14598055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
    Jatoi A; Dakhil SR; Nguyen PL; Sloan JA; Kugler JW; Rowland KM; Soori GS; Wender DB; Fitch TR; Novotny PJ; Loprinzi CL
    Cancer; 2007 Sep; 110(6):1396-403. PubMed ID: 17674351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation.
    Moutsopoulos NM; Katsifis GE; Angelov N; Leakan RA; Sankar V; Pillemer S; Wahl SM
    Ann Rheum Dis; 2008 Oct; 67(10):1437-43. PubMed ID: 18198195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept in the treatment of palmoplantar pustulosis.
    Bissonnette R; Poulin Y; Bolduc C; Maari C; Provost N; Syrotuik J; Poulin-Costello CM; Nigen S
    J Drugs Dermatol; 2008 Oct; 7(10):940-6. PubMed ID: 19112757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current status of treatment for inclusion-body myositis.
    Griggs RC
    Neurology; 2006 Jan; 66(2 Suppl 1):S30-2. PubMed ID: 16432142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.
    Zachariae C; Mørk NJ; Reunala T; Lorentzen H; Falk E; Karvonen SL; Johannesson A; Claréus B; Skov L; Mørk G; Walker S; Qvitzau S
    Acta Derm Venereol; 2008; 88(5):495-501. PubMed ID: 18779890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.
    Stone JH; Holbrook JT; Marriott MA; Tibbs AK; Sejismundo LP; Min YI; Specks U; Merkel PA; Spiera R; Davis JC; St Clair EW; McCune WJ; Ytterberg SR; Allen NB; Hoffman GS;
    Arthritis Rheum; 2006 May; 54(5):1608-18. PubMed ID: 16646004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isokinetic strength testing for evaluating the efficacy of intravenous immune globulin therapy for inclusion body myositis.
    Dasque F; Laroche M; Marque P; Le Vourc'h P; Moulinier L; Maziéres B; Roques CF
    Rev Rhum Engl Ed; 1995 Oct; 62(9):598-601. PubMed ID: 8574634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a combination treatment of an intensive rehabilitation program and etanercept in patients with ankylosing spondylitis: a pilot study.
    Lubrano E; D'Angelo S; Parsons WJ; Serino F; Tanzillo AT; Olivieri I; Pappone N
    J Rheumatol; 2006 Oct; 33(10):2029-34. PubMed ID: 17014018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.